Clinical trials
Carcinoma clinical trials
Below are recruiting carcinoma clinical trials, each written for real people, not researchers. We’re tracking 3,179 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07298577Enrolling by invitation
Using blood test and ultrasound to find early liver cancer in Asia
This study tests whether adding a simple blood test (GAAD score) to a routine liver ultrasound can find early-stage liver cancer sooner in people with chronic liver conditions. It aims to improve detection in Asian populations at risk.
Bangkok Noi, BangkokAges 18 years+ - NCT07186530Enrolling by invitation
HPV self-collection for cervical cancer screening
This trial tests a new way for women to screen for cervical cancer by collecting their own sample for HPV testing at home or in a clinic. It aims to make screening easier for those who are overdue and may be anxious about a pelvic exam.
Rochester, MinnesotaAges 30–63 - NCT07101900Enrolling by invitationPhase 2
Better imaging for kidney cancer before surgery
This trial tests a new PET/CT scan that uses a special tracer to find clear cell kidney cancer. If you are scheduled for kidney tumor removal, this scan may help your surgeon see the cancer more clearly before surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07046832Enrolling by invitation
Augmented reality needle guidance for soft tissue biopsy
This trial tests a new augmented reality system that helps guide the needle during a soft-tissue biopsy. It may make the procedure more accurate and easier for your doctor.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07016737Enrolling by invitationPhase 3
Chemotherapy and radiation for returning esophageal cancer
This trial tests if adding radiation before and after standard chemotherapy can help people whose esophageal cancer has come back after initial treatment. It aims to improve control of the cancer while keeping side effects manageable.
Nanjing, JiangsuAges 18 years+ - NCT06861114Recruiting
Urine test to detect liver cancer return after surgery
This study tests if a simple urine test can help find early signs of liver cancer coming back after surgery. Patients with early-stage liver cancer who have surgery may join to help improve follow-up care.
Guangzhou, GuangdongAges 18–75 - NCT06852144Enrolling by invitation
PET-CT scan for thyroid and parathyroid evaluation
This study looks at how well PET-CT scans can find thyroid or parathyroid problems. The trial uses scans that are already part of your regular care to learn more about these conditions.
Bologna, BoAges 18 years+ - NCT06843681Enrolling by invitationPhase 2
Trastuzumab and Chemo Before Surgery for HER2-Positive DCIS
This trial tests giving trastuzumab (a targeted drug) plus a chemotherapy drug called a taxane before surgery for women with HER2-positive ductal carcinoma in situ (DCIS), an early form of breast cancer. The goal is to see if this combination can shrink or eliminate the cancer before surgery.
Guangzhou, GuangdongAges 18–70 - NCT06810895Enrolling by invitation
Immunotherapy plus chemo for recurrent cervical cancer
This trial tests a new immunotherapy drug called cadonilimab (AK104) combined with standard chemotherapy for women whose small cell neuroendocrine cervical cancer has returned or spread. The goal is to see if this combination helps shrink tumors or slow the cancer better than chemotherapy alone.
WuhanAges 18–75 - NCT06763640Enrolling by invitation
TILs as a predictor in nasopharyngeal cancer
This study looks at how immune cells called TILs (tumor-infiltrating lymphocytes) in your tumor tissue might predict outcomes for nasopharyngeal cancer. It may help doctors better understand your cancer and guide future treatment decisions.
Nanchang, JiangxiAges 18–70 - NCT06712017Enrolling by invitation
Radioactive beads treatment for liver cancer in China
This study looks at how patients with liver cancer (HCC) respond to a treatment called SIR-Spheres, which are tiny radioactive beads placed in the liver. It is for people who received this treatment in 2023 or early 2024 and were checked for tumor response within six months after treatment.
Guangzhou, GuangdongAges 18 years+ - NCT06624189Enrolling by invitation
Liver cancer screening decision support for cirrhosis patients
This trial tests a tool to help doctors and patients decide when to screen for liver cancer. It is for people with cirrhosis who have not had imaging in the last 6 months.
New York, New YorkAges 18 years+ - NCT06540508Enrolling by invitation
TACE with targeted immunotherapy for advanced liver cancer
This study looks at whether combining a liver-directed procedure called TACE with tiragolumab and targeted therapy works better for people with unresectable liver cancer that has not spread too far. Researchers will use blood and tissue tests to see how well the treatment works.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06303583Enrolling by invitationPhase 1/Phase 2
Chemo-radiation followed by immunotherapy for esophageal cancer
This trial tests if giving chemotherapy and radiation before surgery, followed by immunotherapy, can improve outcomes for people with a specific type of esophageal cancer that can be surgically removed.
Hangzhou, ZhejiangAges 18–75 - NCT06261190Enrolling by invitation
Active monitoring for low-risk thyroid cancer
This trial tests whether it is safe to avoid immediate surgery and instead monitor small thyroid cancers that are considered low-risk. If you join, doctors will check regularly to make sure the cancer does not grow or spread.
Goyang-siAges 18 years+ - NCT06048926Enrolling by invitation
Carrelizumab with chemoradiation for advanced esophageal cancer
This trial tests combining the immunotherapy drug carrelizumab with standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be surgically removed. It aims to see if this combination can help shrink or control the tumor.
NanjingAges 18–75 - NCT05171335Enrolling by invitationPhase 2
Lenvatinib plus TACE before transplant for large liver cancer
This trial tests whether taking lenvatinib (a targeted pill) before a liver procedure called TACE can help people with large hepatocellular carcinoma (HCC) get better results while waiting for a liver transplant. It may help shrink or control the cancer without stopping transplant plans.
Houston, TexasAges 18 years+ - NCT04762459Enrolling by invitationPhase 3
Almonertinib after lung tumor surgery, with or without chemo
This study tests whether almonertinib taken after complete surgery can improve outcomes for people with stage II–IIIA non-small cell lung cancer (NSCLC) that has certain EGFR gene changes. It also compares almonertinib plus chemotherapy versus almonertinib alone to see which approach is safer and works better.
Beijing, Beijing MunicipalityAges 18–130 - NCT05673148RecruitingPhase 2
Adding targeted tumor treatment to standard therapy for limited metastatic colorectal cancer
This trial tests whether adding a precise, targeted treatment to destroy remaining cancer spots (called total ablative therapy) after initial chemotherapy can improve outcomes for people with limited metastatic colorectal cancer. It aims to see if this extra treatment is safe and effective.
Kingman, ArizonaAges 18 years+ - NCT06568016Recruiting
Helping patients get colonoscopy after abnormal stool test
This study tests a new clinic program to help patients complete a colonoscopy if they received an abnormal result from a fecal immunochemical test (FIT), a simple stool test for colon cancer. It focuses on community health centers and aims to make follow-up care easier.
Los Angeles, CaliforniaAges Any age - NCT02471352Recruiting
Share skin samples for dermatology research
This study collects and stores biological samples (biospecimens) from people with skin conditions, people at risk, or healthy volunteers. It helps researchers better understand dermatologic diseases and support future skin research.
Bethesda, MarylandAges 1 day–100 years - NCT06488378RecruitingPhase 1
Axatilimab and olaparib for BRCA/PALB2-mutated breast cancer
This trial tests combining two drugs – axatilimab and olaparib (a PARP inhibitor) – for people with advanced HER2-negative breast cancer that carries a BRCA or PALB2 gene mutation. The goal is to see if this new combination is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT07754409Recruiting
Quality of life during lung cancer treatment with immunotherapy
This study looks at how patients with advanced lung cancer feel during their treatment, which combines chemotherapy, radiation, and an immunotherapy drug. The goal is to understand and improve quality of life during therapy.
GothenburgAges 18 years+ - NCT04534205RecruitingPhase 2/Phase 3
Testing BNT113 plus pembrolizumab versus pembrolizumab alone
This trial studies whether adding BNT113 to pembrolizumab works better and is safe for people with HPV16-positive head and neck cancer that can’t be cured with local treatments. It also compares outcomes to pembrolizumab alone, specifically for tumors that show PD-L1 in testing.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinoma?
- Yes. Clin2 currently lists 3,179 recruiting carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.